Receptors, Vasoactive Intestinal Peptide, Type II
"Receptors, Vasoactive Intestinal Peptide, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pituitary adenylate cyclase-activating peptide receptor subtype found in LYMPHOCYTES. It binds both PACAP and VASOACTIVE INTESTINAL PEPTIDE and regulates immune responses.
MeSH Number(s)
D12.776.543.750.100.665.750
D12.776.543.750.100.900.500
Concept/Terms
Receptors, Vasoactive Intestinal Peptide, Type II- Receptors, Vasoactive Intestinal Peptide, Type II
- Vasoactive Intestinal Peptide Receptor 2
- Vasoactive Intestinal Peptide Receptors, Type II
- VIP Receptors, Type II
- VIP2 Receptor
- Receptor, VIP2
- VIP2 Receptors
- Receptors, VIP2
- Receptors, Pituitary Adenylate Cyclase-Activating Peptide, Type III
- VPAC2 Receptor
- Receptor, VPAC2
- PACAP Receptors, Type III
- PACAP Type III Receptor
- PACAPR-3 Protein
- PACAPR 3 Protein
- Pituitary Adenylate Cyclase-Activating Peptide Receptor Type III
- Pituitary Adenylate Cyclase Activating Peptide Receptor Type III
- Vasoactive Intestinal Peptide 2 Receptor
- VIPR2 Protein
Below are MeSH descriptors whose meaning is more general than "Receptors, Vasoactive Intestinal Peptide, Type II".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.100]
- Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide [D12.776.543.750.100.665]
- Receptors, Vasoactive Intestinal Peptide, Type II [D12.776.543.750.100.665.750]
- Receptors, Vasoactive Intestinal Peptide [D12.776.543.750.100.900]
- Receptors, Vasoactive Intestinal Peptide, Type II [D12.776.543.750.100.900.500]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Vasoactive Intestinal Peptide, Type II".
This graph shows the total number of publications written about "Receptors, Vasoactive Intestinal Peptide, Type II" by people in Harvard Catalyst Profiles by year, and whether "Receptors, Vasoactive Intestinal Peptide, Type II" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2009 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2013 | 1 | 1 | 2 |
Below are the most recent publications written about "Receptors, Vasoactive Intestinal Peptide, Type II" by people in Profiles.
-
Ontogeny of Circadian Rhythms and Synchrony in the Suprachiasmatic Nucleus. J Neurosci. 2018 02 07; 38(6):1326-1334.
-
Low levels of vasoactive intestinal peptide are associated with Chagas disease cardiomyopathy. Hum Immunol. 2013 Oct; 74(10):1375-81.
-
Effect of VIP on intracellular [Ca2+], extracellular regulated kinase 1/2, and secretion in cultured rat conjunctival goblet cells. Invest Ophthalmol Vis Sci. 2013 Apr 23; 54(4):2872-84.
-
Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance. Histol Histopathol. 2012 08; 27(8):1093-101.
-
Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature. 2011 Mar 24; 471(7339):499-503.
-
Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Peptides. 2010 Nov; 31(11):2035-45.
-
Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages. J Cell Mol Med. 2009 Sep; 13(9B):3209-17.
-
Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue. Gynecol Endocrinol. 2005 Jun; 20(6):327-33.
-
Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int J Oncol. 2005 Jun; 26(6):1629-35.
-
Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell Signal. 2001 Dec; 13(12):887-94.